Systemic Immune-Inflammation Index as a Predictor of Progression in Melanoma: A Retrospective Cohort Study

The SII independently predicted 12-month disease progression in melanoma, identifying high-risk patients even within early stages. These findings support its role as a simple, reproducible, and low-cost biomarker for preoperative risk assessment and individualized follow-up. Future prospective multicenter studies with larger cohorts and extended follow-up are warranted to validate these results and to better define the clinical utility of SII as part of comprehensive melanoma risk stratification strategies.